



## **ELEKTA'S BOARD DECIDES ON REPURCHASE OF OWN SHARES**

### **PRESS RELEASE**

Stockholm, Sweden, June 14, 2006

**The Board of Directors of Elekta has decided to utilize the authorization the Board received from the Annual General Meeting on September 21, 2005, to repurchase shares in the company.**

Elekta's distribution policy is to distribute 20 percent or more of net profits to shareholders in the form of dividends, share repurchases or comparable measures. Elekta's Annual General Meeting on September 21, 2005 resolved to authorize the Board to decide on the acquisition of a maximum of 10 percent of the total number of shares in the company.

Based on the strong underlying operational performance and financial position the Board decided today, June 14, 2006, to mandate the executive management to initiate on appropriate occasions the repurchase of shares in an amount of SEK 100 M, but maximized to 1.100.000 shares.

As of today, Elekta does not own any of its own shares. A repurchase of 1.100.000 shares is corresponding to 1.2 percent of the total number of outstanding shares in the company. Elekta intends to suggest to the AGM that repurchased shares are cancelled.

Purchases will be made on the Stockholm Stock Exchange and to a price within the spread at the time of purchase. Purchases can be made during the time until next Annual General Meeting.

\*\*\*\*\*

#### **For further information, please contact:**

Peter Ejemyr  
Group VP Corporate Communications, Elekta AB  
Tel: +46 733 611 000  
e-mail: peter.ejemyr@elekta.com

#### **About Elekta**

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife<sup>®</sup> for non-invasive treatment of brain disorders and Elekta Synergy<sup>®</sup> for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 1850 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit [www.elekta.com](http://www.elekta.com).